Deals, Partnering

Wyeth and Catalyst Biosciences have formed an exclusive worldwide collaboration for discovery, development and commercialization of Factor VIIa products to treat hemophilia and other bleeding conditions

Posted on 30 June 2009

Total payments under the collaboration, including an upfront payment of $21 million, research funding and milestone payments, could exceed $500 million, exclusive of royalty payments.

Print Friendly, PDF & Email

Leave a Reply

 

cabannerad300x150new4gif
rauconbadgejpg
e78banner300x150animgif
cpbannerad300x150new1gif
e79banner300x150gif
e78banner300x150animgif